Close Menu

NEW YORK – SpeeDx said on Monday it has agreed with Laboratory Corporation of America to codevelop diagnostic tests . The agreement focuses on assays for women's health and infectious diseases.

SpeeDx and LabCorp will work together to codevelop and introduce new molecular tests using SpeeDx's proprietary technology, the Australia-based firm said in an email. Financial terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.